Corxel Pharmaceuticals closed a $287 million Series D to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist, through ongoing U.S. phase II trials and planned global phase II studies, and to prepare phase III programs. The company said funds will also support diabetes programs and other cardiometabolic assets. Corxel reiterated plans to convert Chinese‑sourced chemistry into a global clinical development strategy, with the financing aimed at expediting regulatory interactions and larger, multi‑region trials. Investors and coverage highlight that demand for oral GLP‑1 options continues to attract large private capital infusions. Why it matters: sizable private rounds for GLP‑1 candidates show venture and crossover appetite to fund oral alternatives to injectables, and they signal competition pressure on incumbents. Expect accelerated regulatory strategy work and manufacturing scale‑up activity.